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Abstract
Introduction: Patients with chronic low back pain (cLBP) have high rates of comorbid psychiatric disorders, mainly
depression. Recent evidence suggests that depressive symptoms and pain, as interacting factors, have an effect on
the circulating levels of inflammatory markers relevant to coronary artery disease. Our previous work showed a
higher serum level of an inflammatory marker tumour necrosis factor-alpha (TNFa) in patients with cLBP, which did
not correlate with intensity of low back pain alone. In the present study we investigated the cross-sectional
associations of depressive symptoms, low back pain and their interaction with circulating levels of TNFa.
Methods: Each group of 29 patients with cLBP alone or with both cLBP and depression was age-matched and
sex-matched with 29 healthy controls. All subjects underwent a blood draw for the assessment of serum TNFa and
completed a standardised questionnaire regarding medication, depression scores according to the German version
of Centre for Epidemiological Studies Depression Scale (CES-D), pain intensity from a visual analogue scale, and
back function using the Roland and Morris questionnaire. The correlations between TNFa level and these clinical
parameters were analysed.
Results: There were no differences in TNFa level between cLBP patients with and without depression. Both cLBP
patients with (median = 2.51 pg/ml, P = 0.002) and without (median = 2.58 pg/ml, P = 0.004) depression showed
significantly higher TNFa serum levels than healthy controls (median = 0 pg/ml). The pain intensity reported by
both patient groups was similar, while the patients with depression had higher CES-D scores (P < 0.001) and worse
back function (P < 0.001). The variance analysis showed that the interaction between TNFa level and pain intensity,
CES-D scores, sex, body mass index and medication was statistically significant.
Conclusions: Depression as a comorbidity to cLBP did not influence the serum TNFa level. It seems that TNFa
somehow acts as a mediator in both cLBP and depression, involving similar mechanisms that will be interesting to
follow in further studies.
Introduction
Patients with chronic low back pain (cLBP) very often
additionally present psychiatric disorders, mostly affec-
tive disturbance. The most common of these disorders
is depression. Equally, depression is frequently asso-
ciated with pain. Some 30 to 60% of cases of depression
are accompanied by pain, and vice versa [1]. Pain is a
major predictor of depression and anxiety, and depres-
sion seems to be an important predictor for work
disability of patients with chronic pain [2]. The costs of
medical treatment for cLBP patients with depression
was found to be 2.8 times higher than those for patients
without depression [3], and the economic cost of
depressive disorders is higher in the presence of coexist-
ing pain [4]. The accompanying depression should
therefore be recognised early and taken into account in
the treatment strategy for chronic pain [5-8].
To date, however, pain and depression have been con-
sidered as separate entities and therefore treated in iso-
lation; the pathophysiology of both pain and depression
are not yet wholly clarified. Patients with pain or
depression have often been observed to present
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common clinical features such as lethargy, anorexia [9],
sleepiness [10], hyperalgesia [11], reduction in grooming
[12] and failure to concentrate [13], which indicates that
pain and depression may share some aspects of patho-
physiology represented by common pathways and
neurotransmitters.
Over the past decade, numerous studies have demon-
strated that cytokines seem to play an important role in
both pain and depression, respectively [14-19]. Cyto-
kines can, however, act as a central link between pain
and depression [20]. This knowledge stimulates our
interest in the potential involvement of immune impair-
ment in coexisting cLBP and depression.
Our previous work revealed elevated TNFa serum
level in patients with cLBP, and that confounding para-
meters such as age, sex, body mass index, alcohol, cigar-
ettes, pain rating and back function did not influence
the TNFa serum level [21]. This observation prompts
the question: which factors did influence the TNFa
serum level?
To date, no studies have investigated the TNFa profile
in coexisting pain and depression. In the prospective
cross-sectional clinical study described here, we set out
to determine whether comorbid depression might affect
the TNFa serum level in patients with low back pain, or
whether TNFa might regulate both pain and depression
together. Our hypothesis was that patients with both
cLBP and depression display higher TNFa serum levels
than patients with cLBP alone and there are cross-sec-
tional associations of pain, depressive symptoms and
their interaction with TNFa in cLBP.
Materials and methods
Subjects
All participants gave informed consent, and the study
was approved by the local ethics committee of the Uni-
versity of Heidelberg, Germany. Participants were conse-
cutively recruited from the Department of Orthopaedic
Surgery of the University of Heidelberg. Each group of
29 patients with cLBP alone or with cLBP together with
depression (cLBP + DE) were matched with 29 healthy
controls by age and sex.
The inclusion criterion for pain was cLBP as the main
symptom, defined as disabling pain of at least 6 months’
duration that led to the patient being on sick leave for
at least 6 weeks. Patients with other pain locations as
their main symptom and patients with multiple major
pain locations were excluded from this study.
The inclusion criteria for the diagnosis of depression
were: an International Statistical Classification of Diseases
and Related Health Problems (10th revision) diagnosis of a
current and at least moderate depressive episode; and a
minimum German version of Centre for Epidemiological
Studies Depression Scale (CES-D) score of 25.
Exclusion criteria in patients and controls were:
tumour disease (diagnosis from history and by radio-
graphic examination/magnetic resonance imaging
(MRI)); trauma/fracture (history and radiographic
examination); inflammatory systemic disease or infec-
tion - for example, spondylodiscitis (blood count and
radiographic evaluation/MRI); nucleus pulposus pro-
lapse with corresponding radicular pain (clinical exam-
ination, MRI); structural pathology of the lumbar spine
- for example, spinal stenosis or spondylolisthesis
(radiographic evaluation/MRI and clinical examina-
tion); rheumatological disease; serious cardiopulmon-
ary, vascular or other internal medical conditions; any
sensorimotor and/or neurological deficits in the lower
extremity (clinical examination); spinal surgery in the
year before admission to multidisciplinary therapy;
radiographically apparent degenerative changes in the
lumbar spine (grade II or above according to the Kellg-
ren and Lawrence classification [22]); or medication
that may influence the TNFa level (for example, oral
or local corticosteroids, aspirin, nonsteroidal anti-
inflammatory drugs, anti-TNFa therapy).
Evaluation
At study entry, the initial evaluation included clinical
and radiographic examination and also MRI of the lum-
bar spine in all patients of the entire study, and blood
count in all patients and controls. Patients were evalu-
ated by standardised questionnaires and physical exami-
nations, including analysis of blood samples.
The average pain intensity of all patients was deter-
mined from a visual analogue scale recording from 0
(no pain) to 10 (severe pain) during the past 24 hours
and the past week. Measures of pain-related disability
was assessed using the Roland and Morris questionnaire
[23], which is a self-administered questionnaire consist-
ing of 24 items chosen to reflect varied activities of daily
living. An item receives a score of 1 if it is checked as
applicable by the respondent, and a score of 0 if it is
not marked. Accordingly, total scores can vary from 0
(no disability) to 24 (severe disability).
The CES-D is a well-established self-reporting instru-
ment to assess the level of depression, with 20 items and a
potential overall score of 0 to 60. It has high specificity
(94%) for the identification of acute depression if a score
of at least 23 points is reached and the correlation coeffi-
cient to other instruments for measuring depression, such
as the Hamilton Depression Scale, is acceptable (r = 0.49)
and increases with recovery from depression (r = 0.86)
[24]. To identify other confounding factors, at each time
point the patients filled in this standardised questionnaire
about depression (CES-D), sleep duration, alcohol and
nicotine consumption, and exercise. To identify confound-
ing factors of medication, the drug intake in the two
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groups was studied accordingly to the Anatomical Thera-
peutic Chemical Classification System.
Determination of cytokine levels in serum
At the given time points, venous blood was taken from
the cubital vein between 8:00 and 9:00 am. Blood sam-
ples were centrifuged at 2,000 rpm at 4°C within 30
minutes of withdrawal, and serum was stored at -80°C.
TNFa serum levels were analysed in duplicate using a
Bio-Plex cytokine assay (Bio-Rad Laboratories, Munich,
Germany) according to the manufacturer’s instructions.
The median fluorescence intensity of standards and
patient samples were determined. Using the Bio-Plex
Manager software, serum levels of TNFa were deduced
from the standard curve. The intra-assay coefficient of
variation was 5 to 10%.
Statistical analysis
The nonparametric Mann-Whitney test was used to
compare groups and was adjusted with Bonferroni cor-
rection. Correlations between the individual groups and
cytokines were investigated using Pearson correlation
analysis. Variance analysis was used to evaluate the
interaction between TNFa level, pain intensity and
depression scores. Drug intake was analysed as cap-
tured/noncaptured without considering the dose.
P < 0.05 was considered statistically significant; P < 0.01
was highly significant. The data were analysed using
SPSS 15.0 software (SPSS, Chicago, IL, USA).
Results
TNFa serum levels
The circulating TNFa serum levels of patients with
and without depressive symptoms were 2.51 pg/ml and
2.58 pg/ml (median), respectively (Figure 1). The levels
were significantly higher than those of healthy controls
(0.1 pg/ml) (P = 0.002 for cLBP + DE, P = 0.004 for
cLBP). No differences in TNFa levels between the
cLBP + DE group and the cLBP group were seen in
this study.
Clinical characteristics between groups
Table 1 presents the clinical characteristics of partici-
pants. Overall there were no statistically significant differ-
ences for age, sex, and body mass index between all three
groups. The reported sleep duration, exercise level, or
alcohol and nicotine consumption in the past 24 hours
within the three groups were comparable (P > 0.05). Even
the pain intensity of both patient groups did not differ
from each other (P > 0.05). Patients with both cLBP and
depressive symptoms, however, had significantly higher
CES-D scores (P < 0.001) (Figure 1) and worse back func-
tion (P < 0.001) than patients with cLBP alone. The med-
ication (inclusive antidepressants) intake between the
two groups was contrastable, except that patients in the
cLBP + DE group were taking significantly more nonster-
oidal anti-inflammatory drugs (M01A) than patients with
cLBP alone at T0 (P = 0.037).
Correlation between TNFa serum level and confounding
factors
In an unadjusted analysis, no correlation was found
between TNFa serum level and age, sex, body mass
index, pain intensity, CES-D score or back function. The
single correlation was found between the TNFa serum
level and intake of analgesics in the cLBP + DE group
(P = 0.027 > 0.005, S = -0.411), however, this single
correlation disappeared after assessment of all variables
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Figure 1 TNFa serum levels. Serum levels of proinflammatory cytokine TNFa (pg/ml, median), pain intensity and depression (DE) scores in
patients with chronic low back pain (cLBP) and in healthy controls (HC). ***P < 0.001, **P < 0.01, differences between patient group and healthy
controls. CES-D, Centre for Epidemiological Studies Depression Scale.
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(as there were 11 variables in this study, correlation
should be P < 0.05/11 = 0.005).
In the variance analysis, using TNFa as a conditioned
variable presented no significant interactions between
TNFa, pain intensity in the past 24 hours (P = 1.000)
and CES-D scores (P = 1.000).
Discussion
Many separate studies have shown that the proinflam-
matory cytokine TNFa may play a role in the pathophy-
siology both of pain and depression. TNFa is
responsible for the triggering of mechanical nociception
[25], peripheral sensitisation of nociceptors [26] and
central sensitisation of posterior horn neurons [27]. In a
chronic constructive injury model, levels of TNFa and
IL-6 were upregulated when the spinal nervous system
was chronically injured [28-31]. Administration of
TNFa inhibitor countered the associated pain behaviour
and hyperalgesia [32,33]. The role of TNFa in pain was
reported by many clinical studies of chronic pain [34],
neuropathic pain [35,37] and fibromyalgia syndrome
[38,39]. Concerning the role of TNFa in depression, a
lot of studies demonstrated significantly higher TNFa
levels in major depressive disorder patients compared
with normal controls [40,44] and a decrease of these
levels after treatment with antidepressants, then reach-
ing similar levels to healthy controls [40].
A new observation from the current study is detection
that the quantity of serum TNFa from patients with
cLBP was not intensified with coexisting pain and
depressive symptoms. Patients with both pain and
depression or patients with pain alone showed no differ-
ence of circulating TNFa level. The interaction between
TNFa level and pain intensity or depression scores was
not statistically significant. It seems that the TNFa level
related to depression or to pain may be regulated by
the same mechanism. There are several plausible
mechanisms that could explain these results and the
relationship between pain, depression and TNFa.
Stresses could be a common source of inflammatory
response in the body of both pain and depressive
patients. Increased sympathetic nervous system activa-
tion in response to stress has been suggested to mediate
inflammatory processes [45]. Conceivably, depression
has been induced in many of our patients by stress -
and chronic, persistent pain is the big stressor for the
patients. Exposure to stressful life events such as
bereavement, divorce and academic stress is reported to
cause depression and impairments of cellular immune
function that may affect each other [46-51]. Chronic
stress impaired at least T-helper type 1 responses,
including the TNFa response [49,52]. Stressful life
events coincide with depressive episodes but can also
activate the immune/inflammatory system, leading to
excess secretion of cytokines. In addition, there are
occasional reports of decreased cytokine secretion in
conjunction with the administration of antidepressant
medication [43,53-55].
Recent developments in neuroscience and psychoim-
munology point to the coexistence of pain and depres-
sion. A newly published review pointed out that the
pathophysiologies of pain and depression may overlap
in many respects [56]. Several brain regions are impli-
cated in both major depressive disorder and pain. For
example, the insular cortex [57,58], the prefrontal cor-
tex [59,60], the anterior cingulate cortex [61,62], the
Table 1 Clinical and psychosocial data for all subjects
Healthy controls (n = 29) cLBP + DE
(n = 29)
cLBP
(n = 29)
Sex (female/male) 17/12 17/12 17/12
Age (years) 40.72 (23 to 66) 45.31 (20 to 69) 44.69 (24 to 68)
Body mass index (kg/m2) 27.1 (18.7 to 47.8) 25.1 (18.9 to 37.4) 24.2 (17.7 to 33.3)
Sleep (hours) 6.7 ± 0.7 5.6 ± 1.7 6.4 ± 1.9
Pain 24 hoursa 0 6.30 ± 1.89 5.13 ± 2.30
Pain 7 daysa 0 6.29 ± 1.58 5.19 ± 2.27
CES-D score 5 32.81 ± 9.38* 12.68 ± 6.64
Back function (RM) 0 13.77 ± 5.26* 10.19 ± 5.65
Exercise in past 24 hours (hours) 5.98 ± 2.33 5.68 ± 5.09 5.28 ± 3.95
Alcohol consumption (24 hours) 16% 16% 19%
Nicotine consumption (24 hours) 20% 42% 23%
Medication
Nonsteroidal anti-inflammatory drugs 0 28%* 7%
Opioids 0 24% 28%
Antidepressants 0 24% 17%
Data presented as n, mean (range), mean ± standard deviation or percentage. cLBP, chronic low back pain; DE, depression; CES-D, Centre for Epidemiological
Studies Depression Scale; RM, Roland and Morris [23]. a : Visual analogue scale, 0 to 10. *: P < 0.05.
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amygdala and the hippocampus [63-65] are activated
and/or altered in response to both depression and
pain. Moreover, Robinson [56] verified that shared
neurocircuits and neurochemicals play an important
role connecting the pathophysiologies of depression
and pain disorders.
This knowledge parallels our opinion. We challenge
the widely held cytokine hypothesis of both cLBP and
depression with the alteration of proinflammatory cyto-
kine TNFa.
The common feature between pain and depression in
relation to cytokines is the stress reaction within the
hypothalamic-pituitary-adrenal (HPA) axis that exists in
patients with cLBP and in those with depression. In ani-
mals, stress can activate proinflammatory pathways in the
brain by activation of microglial cells [66,67]. In humans,
modulation of the immune system by stress is well
known [68]. Studies of chronic and acute stress in models
of human stress have shown higher circulating levels of
IL-6 and TNFa than in controls [68-70]. In general,
depressed patients have an activated HPA axis, increased
levels of cortisol and increased circulating levels of several
proinflammatory cytokines, which can further stimulate
the HPA axis and cortisol production [71].
In individuals with depression there is evidence for
malfunction of cortisol receptors leading to cytokine-
induced cortisol resistance, impaired feedback inhibition
of the HPA axis and sustained activation of immune
cells [72,73]. Depression and psychological distress
sensitise and enhance inflammatory responses to subse-
quent stressful events [68]. The release of proinflamma-
tory cytokines by peripheral immune cells during
inflammation, infection or trauma leads to release of
proinflammatory cytokines by glia in the central nervous
system; these cytokines are associated with induction
and maintenance of pain [74]. Cytokines can enter the
brain and cause alterations in the metabolism of seroto-
nin and dopamine. Additionally, cytokines activate
chronic renal failure, which in turn leads to an increase
in serum glucocorticoid levels [75]. Under physiological
conditions, increased serum glucocorticoid levels induce
an inhibition of the HPA axis. After prolonged stress,
this negative feedback mechanism is disrupted [56].
cLBP as a persistent stressor may possibly also interrupt
the negative glucocorticoid feedback on the HPA axis.
Historically, pain and depression have been conceptua-
lised and treated as discrete phenomena, although they
are highly comorbid disorders. Our findings illustrate the
importance of shared common neurochemicals (TNFa)
in the development of both disorders, and may provide a
suggestion for the physicians - who should carefully eval-
uate patients presenting with either cLBP or depressive
symptoms and tailor their treatment accordingly.
Potential confounding factors for the TNFa serum level
were analysed in the present study. Age, sex, body mass
index, pain intensity, CES-D score and back function did
not correlate with the TNFa serum level individually.
Conclusions
The present study clearly shows that depression as a
comorbidity did not influence the TNFa level in cLBP
patients. In other words, a high TNFa level in patients
with cLBP was not induced by accompanying depression.
Our hypothesis was therefore not supported. Our previous
work and the present study, taken together, confirm that
there is no causal relationship between the TNFa serum
level and cLBP, just as there is no causal relationship
between cytokine alterations in the blood and depressive
disorders. Rather, it seems that TNFa somehow acts as a
mediator in both cLBP and depression, by similar mechan-
isms. In the further study, we followed the development
both of pain intensity and depression scores parallel to the
TNFa level in a longitudinal design of 6 months, and tried
to determine the potential interaction between TNFa,
pain and depression.
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